This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What Makes Edwards Lifesciences (EW) a New Buy Stock
by Zacks Equity Research
Edwards Lifesciences (EW) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stock Investors: Do You Need a Late Cycle Plan?
by Tracey Ryniec
The financial media keeps talking about the economy being in the late cycle but that doesn't mean you can't be buying stocks.
Edwards Lifesciences Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Edwards Lifesciences (EW) gains from recent impressive developments.
Here's Why You Should Invest in Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edwards Lifesciences' (EW) performance.
Edwards Lifesciences Sapien 3 System Recall Classified Class I
by Zacks Equity Research
Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.
Why Is Edwards Lifesciences (EW) Up 3.2% Since Last Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences' (EW) SAPIEN 3 TAVR Receives FDA Nod
by Zacks Equity Research
Edwards Lifesciences (EW) plans a commercial introduction of SAPIEN 3 Ultra in Europe.
HMS Holdings (HMSY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
HMS Holdings (HMSY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here is Why Growth Investors Should Buy Edwards Lifesciences (EW) Now
by Zacks Equity Research
Edwards Lifesciences (EW) could produce exceptional returns because of its solid growth attributes.
Edwards Lifesciences Corporation (EW) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Edwards Lifesciences Corporation (EW).
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
by Zacks Equity Research
Edwards Lifesciences (EW) Q2 results benefit from higher revenues, strong segmental performance and gross margin expansion.
Edwards Lifesciences (EW) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.76% and 4.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Edwards Lifesciences' (EW) Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is likely to deliver a solid second quarter on robust segmental performance.
Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $6 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Edwards Lifesciences Recalls Heart Device on Balloon Rupture
by Zacks Equity Research
Shares of Edwards Lifesciences (EW) decline post product recall news.
CMS' Final Verdict on TAVR: A Boon or Bane for MedTech?
by Urmimala Biswas
While the industry bigwigs are keen to welcome the new CMS ruling, companies like Heart Valve Voice US are not lagging to pen their resistance against a revised policy.
HOLX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
DexCom and Companion Medical Collaboration to Support CGM
by Zacks Equity Research
The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.
Why Is Edwards Lifesciences (EW) Down 2.9% Since Last Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HOLX vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $4 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Masimo Gets CE Mark for ANI Module, Enhances Root Platform
by Zacks Equity Research
Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.
Edwards Lifesciences (EW) Q1 Earnings Beat, EPS View Raised
by Zacks Equity Research
Edwards Lifesciences (EW) gains on strong segmental contributions in Q1.
Edwards Lifesciences Takes Over CAS Medical Systems for $100M
by Zacks Equity Research
This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.